Switching, Substitution & Quotas: Irish Govt Wants Views On Boosting Biosimilars
Executive Summary
Stakeholders are being asked to respond to a consultation on what steps can be taken to increase the use of biosimilars in Ireland. The generics and biosimilars industry body Medicines for Ireland has welcomed the move but says it has come very late in the day.
You may also be interested in...
Ireland Relaxes Biosimilar Switching Stance
The Irish medicines regulator, the HPRA, is proposing to revamp its guidance on biosimilar medicines and to take a more flexible attitude to biosimilar interchangeability and switching. The guidance is expected to feed into a future national biosimilars policy.
Ireland Relaxes Stance On Biosimilar Switching
The Irish medicines regulator, the HPRA, is proposing to revamp its guidance on biosimilar medicines and to take a more flexible attitude to biosimilar interchangeability and switching. The guidance is expected to feed into a future national biosimilars policy.
CHMP OKs First EU Biosimilar Herceptin, And Another Version Of Humira
Samsung Bioepis’s Ontruzant is set to be the first biosimilar version of Roche’s Herceptin on the EU market after getting the all-clear from the EMA’s CHMP on Sept. 15. The committee has also OKd another version of AbbVie’s Humira, this time from Boehringer Ingelheim.